Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM -1.32%72 Dividend Yield % is 0.00% as of Jul. 15, 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.16 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 237 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 421940.51% on this metric.
As of today (2026-07-15), the Trailing Annual Dividend Yield of Orion Pharma is 0.00%.
The historical rank and industry rank for Orion Pharma's Dividend Yield % or its related term are showing as below:
During the past 12 years, the highest Dividend Yield of Orion Pharma was 5.86%. The lowest was 0.00%. And the median was 2.99%.
DHA:ORIONPHARM's Dividend Yield % is not ranked *
in the Utilities - Independent Power Producers industry.
Industry Median: 3.33 * Ranked among companies with meaningful Dividend Yield % only.
During the past 12 months, Orion Pharma's average Dividends Per Share Growth Rate was -100.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -5.90% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was -6.10% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was -5.50% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Orion Pharma's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Dividend Yield % Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Dividend Yield % vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Dividend Yield % falls into.
Orion Pharma (DHA:ORIONPHARM) has a Dividend Yield % of 0.00% as of Jul. 15, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #999999 out of 237 companies in the Utilities - Independent Power Producers industry.
Is Orion Pharma's Dividend Yield % too high?
Orion Pharma's current Dividend Yield % is 0.00%. Based on the distribution chart, Orion Pharma ranks #999999 out of 237 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Dividend Yield % compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #999999 out of 237 companies for Dividend Yield %. This places Orion Pharma in the lower half of its industry. The industry median Dividend Yield % is 3.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for an Utilities - Independent Power Producers company?
The median Dividend Yield % among Utilities - Independent Power Producers companies is 3.33, based on 237 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Dividend Yield % is 3.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.16, compared to a current price of BDT29.90 — trading 48.3% above its estimated fair value. The current Dividend Yield % is 0.00%. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Dividend Yield % is 0.00% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT29.90 is trading 48.3% above its estimated GF Value™ of BDT20.16.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Dividend Yield %: 0.00%
GF Value™: BDT20.16 vs. price of BDT29.90 (48.3% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
